Harry A.

Director, Process Development @Editas Medicine

Cambridge, MA, US
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Sep 2022 — Present

Director, Process Development @Editas Medicine

View department →

Cambridge, MA, US

Provided scientific, tactical, and strategic leadership to develop workflows suitable for clinical and commercial manufacturing for CRISPR-based engineered cell medicines within Editas’ ex vivo product portfolio Supported GMP production and release of 300+ autologous, EDIT-301 drug substance intermediate, and 60+ drug product (DP) batches used in Ruby (Pivotal) and EdiThal (Phase 1) trials achieving >98% manufacturing success rate

EDUCATION

2008 — 2014

Massachusetts Institute of Technology

Doctor of Philosophy (PhD), Chemical Engineering

2004 — 2008

Carnegie Mellon University

Bachelor of Science (B.S.), Chemical Engineering

SKILLS

Microsoft ExcelUv/VisMicrofluidicsConfocal MicroscopyPrimary Cell IsolationBiological EngineeringImmunostainingData AnalysisMass TransferChemistryMicrofabricationParticle Size AnalysisSpectroscopyCell CountingCell Based AssaysStatisticsEngineeringGraphpad PrismFlow CytometryMammalian Cell CultureScanning Electron MicroscopyEmulsionsMicroscopyHomogenizationAspen PlusFlowjoFluid DynamicsPhotolithographyChemical EngineeringAutocadMatlabMicrosoft OfficeResearchAseptic Technique

ABOUT HARRY A.

Strategic technical leader solving complex manufacturing challenges and enabling reliable supply of innovative therapies

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.